// App-Quantinova.ai

2220 : Effect of semaglutide on alanine aminotransferase in subjects with type 2 diabetes and high cardiovascular risk

Researchers

Presenter

  • Arun J. Sanyal

Principal Investigators

  • Morten Hansen

  • Martin Linder

  • Philip N. Newsome

Medical Centers

  • Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, VA

  • Novo NordiskA/S, Soborg, Denmark

  • Liver Unit, Queen Elizabeth Hospital Birmingham NHS Trust, Birmingham, United Kingdom

Locations

  • United States

  • Denmark

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Chronic kidney disease

  • Fatty Liver Disease

  • Type 2 diabetes mellitus

  • Hepatic fibrosis

  • Renal disease

  • Hyperglycemia

  • Diabetes

  • Nonalcoholic fatty liver disease

  • Nonalcoholic steatohepatitis

Biomarkers

  • Alanine transaminase

  • Aspartate aminotransferase

  • Hemoglobin A1c

  • Human albumin

Drug/Treatment

  • Semaglutide

  • Intranasal glucagon

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Superiority

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved